C2i Genomics, AstraZeneca to collaborate on MRD test for clinical R&D

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

C2i Genomics extended its collaboration with AstraZeneca to evaluate the potential of whole-genome minimal residual disease testing across solid cancers, with the goal of enhancing oncology treatment, supporting clinical trial recruitment, and monitoring. 

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Positive high-level results from the EMERALD-1 phase III trial showed Imfinzi (durvalumab) in combination with transarterial chemoembolization, or TACE, and bevacizumab demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival versus TACE alone in patients with hepatocellular carcinoma eligible for embolization. The trial continues to follow the secondary endpoint of overall survival.

Login